George C. Prendergast

George C. Prendergast (born 1961) is an American cancer research scientist, who is President and CEO of Lankenau Institute for Medical Research.[1] Co-leader of the Program in Cancer Cell Biology & Signaling at Kimmel Cancer Center, Thomas Jefferson University;[2] and former Editor-in-Chief of Cancer Research, the most highly cited journal in the field, a journal of the American Association for Cancer Research

Selected publications
  • Muller, AJ; Duhadaway, JB; Donover, PS; Sutanto-Ward, E; Prendergast, GC (2005). "Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy". Nature Medicine. 11 (3): 312. doi:10.1038/nm1196. PMID 15711557.
  • Prendergast, G; Ziff, E (1991). "Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region". Science. 251 (4990): 186. Bibcode:1991Sci...251..186P. doi:10.1126/science.1987636. PMID 1987636.
  • Prendergast, GC; Lawe, D; Ziff, EB (1991). "Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation". Cell. 65 (3): 395. doi:10.1016/0092-8674(91)90457-A. PMID 1840505.
George C. Prendergast
Born
Philadelphia, Pennsylvania
Alma materPrinceton University (PhD)
Yale University (MS)
University of Pennsylvania (BA)
Awards1995 Pew Scholar in the Biomedical Sciences
Scientific career
FieldsOncology, Molecular biology, Oncoimmunology
InstitutionsLankenau Institute for Medical Research
DuPont Pharmaceuticals Company
The Wistar Institute
Merck Research Laboratories
Howard Hughes Medical Institute

References
  1. "The Lankenau Institute for Medical Research - George C. Prendergast, PhD". Retrieved 29 December 2013.
  2. Program in Cancer Cell Biology & Signaling, Kimmel Cancer Center, Thomas Jefferson University
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.